June 14, 2024

FDA panel endorses widespread use of Pfizer COVID-19 vaccine

A U.S. government advisory panel’s decision is a major step toward a vaccination campaign that could finally conquer the outbreak.

A U.S. government advisory panel has endorsed Pfizer’s coronavirus vaccine, in a major step toward an epic vaccination campaign that could finally conquer the outbreak.

The Food and Drug Administration is expected to follow the recommendation issued Thursday by its expert advisers. The advisory group, in 17-4 vote with one abstention, concluded that the shot appears safe and effective against the coronavirus in people 16 and older.

A final FDA decision is expected within days. Millions of shots would then ship to begin vaccinating health care workers and nursing home residents. Widespread access to the general public is not expected until the spring.

Read More: Fauci: Time for Black community ‘to put skepticism aside’ about vaccine

A U.S. government advisory panel convened on Thursday to decide whether to endorse large-scale use of Pfizer’s COVID-19 vaccine to help conquer the outbreak that has killed close to 300,000 Americans.

A pharmacist labels syringes in a clean room where doses of COVID-19 vaccines will be handled, Wednesday, Dec. 9, 2020, at Mount Sinai Queens hospital in New York. (AP Photo/Mark Lennihan)

The FDA panel functions like a science court. During the scheduled daylong session, it was expected to debate and pick apart the data — in public — on whether the vaccine is safe and effective enough to be cleared for emergency use. With unprecedented interest in the normally obscure panel, the FDA broadcast the meeting via Youtube, and thousands logged on.

“The American public demands and deserves a rigorous, comprehensive and independent review of the data,” said FDA’s Dr. Doran Fink, who described agency scientists working nights, weekends and over Thanksgiving to get that done.

The FDA is not required to follow the committee’s advice but is widely expected to do so. Once that happens, the U.S. will begin shipping millions of doses of the shot.

Later this month, the FDA is expected to pass judgment on another vaccine, developed by Moderna and the National Institutes of Health, that has proved about as protective as Pfizer’s. Vaccine candidates by Johnson & Johnson and AstraZeneca are also in the pipeline.

The initial supplies from Pfizer and Moderna will be limited and reserved primarily for health care workers and nursing home patients, with other vulnerable groups next in line until the shots become widely available on demand, something that will probably not happen until the spring.

Read More: Top 10 things Black Americans need to know about the vaccine

The meeting of experts on vaccine development, infectious diseases and medical statistics came as the coronavirus continues surging across much of the world, claiming more than 1.5 million lives, including about 290,000 in the U.S.

Documents created by Pfizer for the meeting with the Food and Drug Administration advisory panel, as Pfizer seeks approval for emergency use of their COVID-19 vaccine are seen on Thursday, Dec. 10, 2020. (AP Photo/Jon Elswick)

Hanging over the meeting was a warning from British officials that people with a history of serious allergic reactions shouldn’t get the vaccine. Government authorities there are investigating two reports of reactions that occurred on Tuesday when Britain became the first country in the West to begin mass vaccinations against the scourge.

Pfizer representatives told the panel they are aware of the British reports but have seen no signs of allergic reactions in their trial of the vaccine.

FDA said results from Pfizer’s large, ongoing study showed that the shot, which was developed with Germany’s BioNTech, was more than 90% effective across people of different ages, races and underlying health conditions, including diabetes and obesity. No major safety problems were uncovered. Common side effects included fever, fatigue and pain at the injection site.

“The data presented in the briefing report were consistent with what we heard before and are really exciting,” said Dr. William Moss, head of Johns Hopkins University’s International Vaccine Access Center. “Nothing that I see would delay an emergency use authorization.”

The meeting also represented an opportunity for regulators to try to boost public confidence in the breakneck development process that has produced the Pfizer vaccine and a string of other upcoming shots with remarkable speed — less than a year after the virus was identified.

The FDA has also faced weeks of criticism from President Donald Trump for not rushing out a vaccine before Election Day.

“There have been a lot of questions about why it takes us so long or are we being rigorous enough?” FDA Commissioner Stephen Hahn said in an interview. “I’m hoping that people will see with our transparency that we have taken a very rigorous stance on this.”

Hahn said the agency had already teed up the process to authorize the vaccine by filling out all the legal paperwork in advance, regardless of the ultimate decision.

Have you subscribed to theGrio’s podcast “Dear Culture”? Download our newest episodes now!

TheGrio is now on Apple TV, Amazon Fire, and Roku. Download theGrio today!

The post FDA panel endorses widespread use of Pfizer COVID-19 vaccine appeared first on TheGrio.

About The Author

Past Interviews

Download Our New App!

Umoja Radio Amazon Mobile AppUmoja Radio Amazon Mobile AppUmoja Radio Android Mobile AppUmoja Radio iPhone Mobile AppUmoja Radio iPhone Mobile App